13 september 2020
14:43
–
The American Gilead, partner of Galapagos in our country, would be close to a takeover of more than 20 billion dollars from the American cancer specialist Immunomedics. That writes The Wall Street Journal.
–
According to the American business newspaper The Wall Street Journal, the American pharmaceutical company Gilead is close to a multi-billion acquisition. The newspaper, which spoke to sources close to the file, says that Gilead would acquire US Immunomedics for over $ 20 billion.
Gilead is known in our country as a partner of the Mechelen biotech company Galapagos. In the summer of 2019, the American pharmaceutical company closed a 4.5 billion euros deal with Galapagos for access rights and exclusivity on all major medicines that the Mechelen biotech company is developing.
–
Rapidly growing oncology
Gilead has made acquisitions in the fast-growing field of oncology in recent years, such as Kite Pharma’s $ 12 billion in 2017 for $ 12 billion, to enhance its drug portfolio and boost sales.
Since Immunomedics’ breast cancer drug Trodelvy was given the green light in April by the US drug watchdog FDA, the oncology company has been a sought-after bride for big pharma.
–
The company has a market value of about $ 10 billion, according to data from the financial news agency Bloomberg, and the stock price has nearly doubled this year.
–
Rival bid
The deal could be announced Monday, according to The Wall Street Journal, although talks could also go wrong and a rival offer could be made, the British business newspaper Financial Times also writes.
–
–
